T1	Participants 864 1047	50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheresis,
T2	Participants 2464 2519	patients with homozygous familial hypercholesterolaemia
